Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CET

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
03/23 DAIICHI SANKYO : to Facilitate New Drug Discovery in 2017 through Collaborative ..
03/21 DAIICHI SANKYO : Daichii questions Singh brothers’ asset declaration
03/20 DAIICHI SANKYO : Ranbaxy’s former promoters refuse to pay Rs 2562 crore to..
03/20 DAIICHI'S RANBAXY PROFITS OUTWEIGH L : Singh brothers
03/17 DAIICHI SANKYO : The National Institutes of Biomedical Innovation, Health and Nu..
03/16 DAIICHI SANKYO : Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA..
03/16 DAIICHI SANKYO : Amring Pharmaceuticals Acquired Six ANDAs
03/15 DAIICHI SANKYO : Announces Large-scale Registry of Venous Thromboembolism (VTE) ..
03/15 Heptares adds Daiichi pain pact to string of R&D deals
03/14 DAIICHI SANKYO : Heptares Therapeutics enters agreement with Daichi Sankyo
More news
Sector news : Pharmaceuticals - NEC
01:49p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/17 ArQule's lead product candidate tivantinib flunks late-stage liver cancer stu..
02/03 FDA rejects Charleston and Daiichi's opioid candidate
01/24 Pancreatic Cancer Field Awaits Sparse Data
01/18 Daiichi launches Japan-based study of breast cancer candidate U3-1402
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials ( JPY)
Sales 2017 943 285 M
EBIT 2017 -
Net income 2017 73 154 M
Finance 2017 299 367 M
Yield 2017 2,73%
P/E ratio 2017 23,43
P/E ratio 2018 25,83
EV / Sales 2017 1,61x
EV / Sales 2018 1,67x
Capitalization 1 817 905 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 412  JPY
Spread / Average Target -5,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..7.17%16 325
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
More Results